RELATED CONTENT
NEWS
- US drug reimbursement moving toward differentiated, cost-saving therapeutics
- Eisai braced for reimbursement challenges ahead of Russia entry
- UCB's epilepsy focus shifting to refractory patients, disease-modifying drugs
- UCB propels Vimpat monotherapy along Keppra path, but can it beat Keppra?
FEATURES
Other Informa Features

